Sponsored diagnostic testing programs for Hypertrophic Cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder marked by abnormal thickening of the heart muscle, most often the left ventricle. This can impair blood flow, cause arrhythmias, and lead to symptoms such as chest pain, shortness of breath, or fainting. Severity varies widely—from asymptomatic cases to significant cardiac complications.
2 programs found for Hypertrophic Cardiomyopathy (HCM)
The Invitae Unlock™ Cardiomyopathy & Arrhythmia program offers no-charge genetic testing for U.S. patients with suspected inherited cardiomyopathy or arrhythmia. The comprehensive panel supports diagnostic clarification, risk assessment, and family variant identification. Eligible patients may access testing at no cost when ordered by a qualified healthcare provider.
Roadmap2Rare (Canada) provides complimentary genetic and biochemical testing for suspected rare diseases, delivered by Revvity Omics in collaboration with Sanofi Canada. The program is designed to address unmet testing needs and is available to Canadian clinicians. Test selection and treatment decisions remain at the discretion of the healthcare professional.
